Dry Powder Inhaler
Sponsors
AZTherapies, Inc., Wake Forest University Health Sciences, Pulmovant, Inc., Rein Therapeutics, AstraZeneca
Conditions
AsthmaAsthma (Diagnosis)COPDCOPD ExacerbationCardiovascular DiseasesFibrosisHealthy VolunteerHealthy Volunteers
Phase 1
Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers
CompletedNCT02482324
Start: 2015-06-30End: 2015-07-31Updated: 2015-07-21
A Study of Inhaled AZD8630 in Adolescents With Asthma
CompletedNCT07065331
Start: 2025-06-11End: 2025-09-19Updated: 2025-10-14
A Phase 1 Study of Mosliciguat in Healthy, Adult Males
Active, not recruitingNCT07185321
Start: 2025-06-10End: 2026-05-31Updated: 2025-09-22
Phase 2
A Study of Mosliciguat in PH-ILD
Active, not recruitingNCT06635850
Start: 2024-10-29End: 2028-01-01Updated: 2026-02-20
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
RecruitingNCT06968845
Start: 2026-02-02End: 2027-12-31Target: 120Updated: 2026-03-31
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RecruitingNCT07333183
Start: 2025-12-23End: 2028-01-31Target: 20Updated: 2026-01-12
Phase 4
Unknown Phase
An open-label, low interventional clinical study investigating error rates (critical and overall) prior to any retraining in correct use of the ELLIPTA dry powder inhaler (DPI) compared to other DPIs including; DISKUS, Turbuhaler, HandiHaler and Breezhaler as a monotherapy or in combination, in adult patients with Chronic Obstructive Pulmonary Disease (COPD) (study 204981)
Active, not recruitingNL-OMON46129
Start: 2017-06-29Target: 360Updated: 2024-02-28
Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler
Not yet recruitingNCT07372573
Start: 2026-02-01End: 2026-07-31Target: 210Updated: 2026-01-28